Investing in Kymera Therapeutics Inc (KYMR) Is Getting More Attractive

Kymera Therapeutics Inc’s recent filing unveils that its Director BVF PARTNERS L P/IL acquired Company’s shares for reported $13.96 million on Jun 30 ’25. In the deal valued at $44.00 per share,317,167 shares were bought. As a result of this transaction, BVF PARTNERS L P/IL now holds 2,798,795 shares worth roughly $122.62 million.

Then, BAKER BROS. ADVISORS LP bought 655,500 shares, generating $28,842,000 in total proceeds. Upon buying the shares at $44.00, the Director now owns 6,117,295 shares.

Before that, Ridloff Elena sold 4,500 shares. Kymera Therapeutics Inc shares valued at $225,000 were divested by the Director at a price of $50.00 per share. As a result of the transaction, Ridloff Elena now holds 0 shares, worth roughly $0.0.

A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who increased its forecast for the stock in early June from “an Equal-weight” to “an Overweight”. B. Riley Securities also remained covering KYMR and has increased its forecast on June 03, 2025 with a “Buy” recommendation from previously “Neutral” rating. BofA Securities revised its rating on June 02, 2025. It rated KYMR as “a Buy” which previously was an “a Neutral”.

Price Performance Review of KYMR

On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -2.19% to $43.81. Over the last five days, the stock has lost -0.70%. Kymera Therapeutics Inc shares have risen nearly 44.97% since the year began. Nevertheless, the stocks have risen 8.90% over the past one year. While a 52-week high of $53.27 was reached on 06/11/25, a 52-week low of $19.44 was recorded on 04/09/25.

Levels Of Support And Resistance For KYMR Stock

The 24-hour chart illustrates a support level at 43.05, which if violated will result in even more drops to 42.30. On the upside, there is a resistance level at 44.51. A further resistance level may holdings at 45.22.

How much short interest is there in Kymera Therapeutics Inc?

A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-06-13, growing by 0.59 million shares to a total of 7.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.0 million shares. There was a rise of 7.75%, which implies that there is a positive sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.